SANTA MONICA, Calif., October 06, 2025--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a ...

The CHMP recommended granting Repatha marketing authorization for: The treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial [HeFH]) or mixed dyslipidemia, as ...

THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha ® (evolocumab) to include ...

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL)cholesterol under control with current ...

Biotech major Amgen, Inc.AMGN announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU. The submissions seek to include data from a phase III ...

Cost watchdog the National Institute for Health and Care Excellence has turned down Amgen’s Repatha - the world’s first approved PCSK9 inhibitor - as an option for people with high cholesterol and ...

For all the talk about new opportunities for consumers to make their own healthcare decisions, much remains out of their control. Nowhere is that more evident than in the prescription drug market, ...

(Reuters) - Amgen Inc, looking to boost use of its potent cholesterol drug Repatha, has cut the medication's U.S. list price by 60 percent to $5,850, the U.S. biotechnology company said on Wednesday.

THOUSAND OAKS, Calif., May 22, 2015 /PRNewswire/ -- Amgen (AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a ...